New Drug Approved for Early Alzheimer’s - The New York Times
WEBJul 2, 2024 · The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
FDA approves a second Alzheimer's drug, Eli Lilly's Kisunla - AP News
WEBJul 2, 2024 · The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22% more slowly in terms of memory and cognitive ability than those who received a dummy infusion.
News Release - Eli Lilly and Company
WEBJul 2, 2024 · Kisunla is the first and only amyloid plaque-targeting therapy that used a limited-duration treatment regimen based on amyloid plaque removal; nearly half of study participants completed their course of treatment with Kisunla in 12 months.
FDA Approves Kisunla (Donanemab) | Alzheimer's Association
WEBCHICAGO, July 2, 2024 — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to approve Kisunla™ (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease ...
FDA approves Eli Lilly's Alzheimer's drug Kisunla - NBC News
WEBThe drug, donanemab, which will be sold under the brand name Kisunla, is a monoclonal antibody infusion given every four weeks. The FDA cleared the drug for use in adults with mild cognitive ...
Alzhiemer's drug Kisunla from Eli Lilly gains FDA approval - USA TODAY
WEBJul 2, 2024 · Kisunla becomes the third amyloid-clearing Alzheimer's drug approved since 2021. Last year, the FDA approved Eisai and Biogen's drug Leqembi but required the drug to provide a...
FDA approves treatment for adults with Alzheimer’s disease
WEBJul 2, 2024 · The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild...
Treatment for Early Symptomatic Alzheimer’s Disease with Kisunla ...
WEBKisunla™ (kih-SUHN-lah) is used to treat adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease. Warnings - Kisunla can cause Amyloid-Related Imaging Abnormalities or “ARIA.”
FDA approves treatment for adults with Alzheimer’s disease
WEBThe U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials.
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the …
WEB2 days ago · Japan is the second major market where Kisunla has received approval. Kisunla was first approved in the United States in July 2024. INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults ...